CA2897348C - Cycloalkyne derivatized saccharides - Google Patents

Cycloalkyne derivatized saccharides Download PDF

Info

Publication number
CA2897348C
CA2897348C CA2897348A CA2897348A CA2897348C CA 2897348 C CA2897348 C CA 2897348C CA 2897348 A CA2897348 A CA 2897348A CA 2897348 A CA2897348 A CA 2897348A CA 2897348 C CA2897348 C CA 2897348C
Authority
CA
Canada
Prior art keywords
saccharide
group
conjugate
azide
spacer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2897348A
Other languages
English (en)
French (fr)
Other versions
CA2897348A1 (en
Inventor
Roberto ADAMO
Francesco Berti
Qi-Ying Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CA2897348A1 publication Critical patent/CA2897348A1/en
Application granted granted Critical
Publication of CA2897348C publication Critical patent/CA2897348C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2897348A 2013-01-15 2014-01-13 Cycloalkyne derivatized saccharides Active CA2897348C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1300707.5 2013-01-15
GBGB1300707.5A GB201300707D0 (en) 2013-01-15 2013-01-15 Compounds and processes
PCT/EP2014/050483 WO2014111344A1 (en) 2013-01-15 2014-01-13 Cycloalkyne derivatized saccharides

Publications (2)

Publication Number Publication Date
CA2897348A1 CA2897348A1 (en) 2014-07-24
CA2897348C true CA2897348C (en) 2022-09-27

Family

ID=47758014

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2897348A Active CA2897348C (en) 2013-01-15 2014-01-13 Cycloalkyne derivatized saccharides

Country Status (16)

Country Link
US (2) US11135300B2 (cg-RX-API-DMAC7.html)
EP (1) EP2945641B1 (cg-RX-API-DMAC7.html)
JP (3) JP6719209B2 (cg-RX-API-DMAC7.html)
CN (1) CN105377282B (cg-RX-API-DMAC7.html)
BR (1) BR112015016817B1 (cg-RX-API-DMAC7.html)
CA (1) CA2897348C (cg-RX-API-DMAC7.html)
CY (1) CY1122822T1 (cg-RX-API-DMAC7.html)
DK (1) DK2945641T3 (cg-RX-API-DMAC7.html)
ES (1) ES2774729T3 (cg-RX-API-DMAC7.html)
GB (1) GB201300707D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20200351T1 (cg-RX-API-DMAC7.html)
LT (1) LT2945641T (cg-RX-API-DMAC7.html)
PL (1) PL2945641T3 (cg-RX-API-DMAC7.html)
PT (1) PT2945641T (cg-RX-API-DMAC7.html)
SI (1) SI2945641T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014111344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes
US20190054127A1 (en) * 2016-03-04 2019-02-21 Euglena Co., Ltd. Antiviral agent and antiviral food
EP4588521A3 (en) 2016-12-30 2025-10-22 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
JP7295571B2 (ja) * 2018-02-05 2023-06-21 国立大学法人 宮崎大学 細胞標識剤及び細胞標識キット
CA3103227A1 (en) 2018-06-14 2019-12-19 Mochida Pharmaceutical Co., Ltd. Novel crosslinked alginic acid
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
EP4200268A4 (en) 2020-08-19 2024-10-16 Vaxcyte, Inc. CARRIER PROTEIN POLYSACCHARIDE CONJUGATION PROCESS
EP4346892A2 (en) * 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2024075506A (ja) * 2022-11-22 2024-06-03 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1777236B8 (en) 2002-03-26 2017-02-22 GlaxoSmithKline Biologicals SA Modified saccharides having improved stability in water for use as a medicament
CN101107010A (zh) 2004-11-01 2008-01-16 布里格海姆妇女医院公司 经修饰的链球菌多糖及其用途
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US8133515B2 (en) * 2007-11-21 2012-03-13 University Of Georgia Research Foundation, Inc. Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds
ITVI20090234A1 (it) * 2009-09-25 2011-03-26 Termotecniche Fraccaro S R L Off Dispositivo per il riscaldamento di ambienti ad alta efficienza energetica, nonche' sistema riscaldante comprendente tale dispositivo
CA2785410A1 (en) 2009-12-23 2011-06-30 Carlos F. Barbas, Iii Tyrosine bioconjugation through aqueous ene-like reactions
EP3604264A1 (en) 2010-04-27 2020-02-05 SynAffix B.V. Fused cyclooctyne compounds
WO2012017701A1 (ja) * 2010-08-05 2012-02-09 株式会社ミュージックゲート いびき防止マスク
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CN103347862B (zh) 2010-09-27 2018-07-20 乔治亚大学研究基金公司 包含潜在的1,3-偶极-官能化合物的方法和由此制备的材料
US20120208722A1 (en) 2010-10-19 2012-08-16 Richard Dluhy Surface enhanced raman spectroscopy platforms and methods
DK2721045T3 (en) 2011-06-20 2017-07-24 Radiomedix Inc COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS
HK1200190A1 (en) * 2011-12-01 2015-07-31 安吉奥开米公司 Targeted enzyme compounds and uses thereof
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes

Also Published As

Publication number Publication date
DK2945641T3 (da) 2020-03-09
EP2945641A1 (en) 2015-11-25
SI2945641T1 (sl) 2020-03-31
JP2020114839A (ja) 2020-07-30
US20210268116A1 (en) 2021-09-02
EP2945641B1 (en) 2020-01-01
BR112015016817B1 (pt) 2020-11-10
LT2945641T (lt) 2020-02-25
BR112015016817A8 (pt) 2019-10-29
CA2897348A1 (en) 2014-07-24
JP2016506905A (ja) 2016-03-07
BR112015016817A2 (pt) 2017-07-11
US20160166704A1 (en) 2016-06-16
GB201300707D0 (en) 2013-02-27
CN105377282A (zh) 2016-03-02
US11135300B2 (en) 2021-10-05
US12409231B2 (en) 2025-09-09
JP7036854B2 (ja) 2022-03-15
HRP20200351T1 (hr) 2020-06-12
CY1122822T1 (el) 2021-05-05
WO2014111344A1 (en) 2014-07-24
CN105377282B (zh) 2020-07-17
JP2019073528A (ja) 2019-05-16
ES2774729T3 (es) 2020-07-22
PT2945641T (pt) 2020-03-26
JP6719209B2 (ja) 2020-07-08
PL2945641T3 (pl) 2020-06-15

Similar Documents

Publication Publication Date Title
US12409231B2 (en) Cycloalkyne derivatized saccharides
US10188719B2 (en) Conjugation of Streptococcal capsular saccharides
EP2616099B1 (en) Immunogenic compositions
ES2812523T3 (es) Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
EP3482770A1 (en) Immunogenic compositions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190107

EEER Examination request

Effective date: 20190107